Is Xenetic Biosciences, Inc. (XBIO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 117.5% / 30% | 0.0% / 30% | 9.99% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 117.5% / 33% | 0.0% / 33% | 9.99% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 89.3% / 33% | 0.0% / 33% | 9.99% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 117.5% / 33% | 0.0% / 33% | 9.99% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 89.3% / 33% | 0.0% / 50% | 9.99% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -81.3% | |
| Net Margin | -90.1% | |
| Return on Equity (ROE) | -40.0% | |
| Return on Assets (ROA) | -23.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$2M |
| Free Cash Flow | -$2M |
| Current Ratio | 8.3 |
| Total Assets | $8M |
Price & Trading
| Last Close | $2.80 |
| 50-Day MA | $2.51 |
| 200-Day MA | $3.00 |
| Avg Volume | 27K |
|
52-Week Range
$1.90
| |
About Xenetic Biosciences, Inc. (XBIO)
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Xenetic Biosciences, Inc. (XBIO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Xenetic Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Xenetic Biosciences, Inc.'s debt ratio?
Xenetic Biosciences, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Xenetic Biosciences, Inc.'s key financial metrics?
Xenetic Biosciences, Inc. has a market capitalization of $6M, and revenue of $3M. The company maintains a gross margin of 100.0% and a net margin of -90.1%. Return on equity stands at -40.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.